106 catalog products · Mass · Sequence · Evidence
Peptide Directory
Every catalog product in one place, with its listed molecular mass, its specified sequence where one is documented, and a short summary of the published research. Masses and sequences are catalog specifications, not lot test results.
| Peptide | Catalog molecular mass | Specified sequence | Research evidence |
|---|---|---|---|
| 5-Amino-1MQ GLP-1 & Metabolic | 159.19 g/mol | Not listed — confirm against lot documents | 5-Amino-1MQ is a non-peptide NNMT research inhibitor. The catalog cites mouse muscle-regeneration work; preclinical findings do not establish human metabolic or anti-aging benefits. |
| Adamax 1032 Da Cognitive | 1032.2 Da | Ac-MEHFPGP-Adamantylglycine-NH₂ | Adamax 1032 Da is listed with an adamantane modification. Semax and P021 studies do not test this construct or establish a stability advantage over Adamax 984 Da.2 cited references → |
| Adamax 984 Da Cognitive | 984.1 Da | Ac-MEHFPGPAG-OH | Adamax 984 Da is a distinct Semax-family catalog construct. Semax rat studies provide background only; no independent direct study of this Adamax construct was verified.1 cited reference → |
| Adipotide (FTPP) GLP-1 & Metabolic | Not listed | Not listed — confirm against lot documents | Adipotide (FTPP) is studied as a targeted agent affecting adipose-tissue blood vessels. Published work includes obese rhesus-monkey experiments; animal findings do not establish human effectiveness or safety. |
| AHK-Cu Recovery & Repair | ~404.5 g/mol | Not listed — confirm against lot documents | AHK-Cu is a copper-peptide research complex. Available evidence is predominantly preclinical and in vitro, not proof of human hair-growth or skin benefits. |
| AICAR GLP-1 & Metabolic | 338.21 g/mol | Not listed — confirm against lot documents | AICAR is a non-peptide compound used in cellular energy-signaling research. Mouse experiments examined oxidative-metabolism genes and endurance, not a demonstrated substitute for exercise in people. |
| AOD 9604 GLP-1 & Metabolic | 1815.08 g/mol | Not listed — confirm against lot documents | AOD-9604 is a growth-hormone-fragment analogue studied in fat-metabolism research. The available catalog narrative does not substantiate a clinical benefit or a claim that GRAS status confirms this vial’s safety. |
| ARA-290 Specialty | Not listed | Not listed — confirm against lot documents | ARA-290 is an erythropoietin-derived peptide. Small condition-specific human studies examined neuropathy-related outcomes, not general nerve repair or absence of adverse effects. |
| Argireline (Acetyl Hexapeptide-8) Specialty | 888.99 g/mol | Not listed — confirm against lot documents | Argireline, or acetyl hexapeptide-8, has small topical-formulation studies of wrinkle appearance. Formulation and skin penetration matter; these findings do not validate a research vial as a skincare treatment. |
| B7-33 Specialty | Not listed | Not listed — confirm against lot documents | B7-33 is a relaxin-related research peptide studied in RXFP1 signaling. Preclinical fibrosis models provide experimental context, not evidence of clinical cardiac or renal benefit. |
| Bonothyrk Bioregulators | ~720 g/mol | Not listed — confirm against lot documents | Bonothyrk has limited product-specific literature described in the catalog. Broader short-peptide bioregulator studies cannot establish this material’s identity or thyroid-related clinical effects. |
| BPC-157 Recovery & Repair | 1419.53 g/mol | Not listed — confirm against lot documents | BPC-157 research includes rat Achilles-tendon injury and in-vitro tendon-cell experiments. These studies examined outgrowth, survival and migration, not established healing benefits in humans. |
| Bronchogen Bioregulators | Not listed | Not listed — confirm against lot documents | Bronchogen is listed for respiratory-system research. The catalog does not supply enough product-specific study detail to substantiate clinical respiratory benefits. |
| Cagrilintide GLP-1 & Metabolic | 3789.43 g/mol | Not listed — confirm against lot documents | Cagrilintide is an amylin analogue studied in metabolic research. Combination findings with semaglutide must be distinguished from results for cagrilintide alone and from this research vial. |
| CagriSema (Cagrilintide + Semaglutide) GLP-1 & Metabolic | Mixture | Not listed — confirm against lot documents | CagriSema research includes REDEFINE 1, which studied coadministered cagrilintide and semaglutide in adults with overweight or obesity. That preparation does not validate this premixed research vial.1 cited reference → |
| Cardiogen Bioregulators | Not listed | Not listed — confirm against lot documents | Cardiogen is listed for cardiac-system research. The available narrative does not substantiate claims of reduced cardiovascular events or improved clinical heart function. |
| Cartalax Bioregulators | Not listed | Not listed — confirm against lot documents | Cartalax is listed for cartilage and extracellular-matrix research. The catalog does not provide enough study detail to establish clinical joint-mobility or pain outcomes. |
| Cerebrolysin Cognitive | <10000 g/mol (peptide mixture) | Not listed — confirm against lot documents | Cerebrolysin literature concerns defined peptide-mixture preparations in stroke and brain-injury studies. Findings and evidence quality are condition-specific and do not verify this catalog mixture. |
| Cetrorelix Reproductive | 1431.06 g/mol | Not listed — confirm against lot documents | Cetrorelix is a GnRH antagonist with clinical fertility literature. Findings concern defined clinical preparations and protocols, not the identity or effects of this research inventory. |
| Chonluten Bioregulators | Not listed | Not listed — confirm against lot documents | Chonluten is listed for respiratory and mucosal research. Evidence detail is insufficient here to establish barrier improvement or benefits from combining it with Bronchogen. |
| CJC-1295 No DAC + GHRP-6 Blend Growth Hormone | Mixture | Not listed — confirm against lot documents | CJC-1295 No DAC and GHRP-6 are combined in this catalog blend. Individual receptor studies do not establish blend efficacy or equivalence to CJC-1295 with DAC. |
| CJC-1295 No DAC + Ipamorelin Blend Growth Hormone | Mixture | Not listed — confirm against lot documents | CJC-1295 No DAC and ipamorelin have separate research contexts. Those findings do not establish the effects or synergy of this fixed commercial blend. |
| CJC-1295 w/DAC Growth Hormone | Not listed | Not listed — confirm against lot documents | CJC-1295 with DAC has published characterization and short human studies of growth hormone and IGF-I responses. This evidence concerns the DAC construct, not CJC-1295 No DAC or a commercial blend.3 cited references → |
| Cortagen Bioregulators | Not listed | Not listed — confirm against lot documents | Cortagen is listed for nervous-system research. Broad descriptions of cognition and cellular protection in the catalog do not substantiate clinical cognitive benefits. |
| Dihexa Cognitive | 574.71 g/mol | Not listed — confirm against lot documents | Dihexa has preclinical literature on synapse formation and cognition-related measures in rats. These experiments do not establish human cognitive benefits or a universal potency comparison with BDNF. |
| DSIP Cognitive | 848.82 g/mol | Not listed — confirm against lot documents | Delta sleep-inducing peptide (DSIP) has older human sleep studies and experimental literature. That research does not establish consistent insomnia benefits or absence of tolerance and adverse effects. |
| Ecnoglutide GLP-1 & Metabolic | ~4400 g/mol | Not listed — confirm against lot documents | Ecnoglutide has phase 3 clinical literature in type 2 diabetes. EECOH-1 examined a defined monotherapy preparation; results do not verify this material or explain every effect through receptor bias.1 cited reference → |
| Eloralintide GLP-1 & Metabolic | ~4300 g/mol | Not listed — confirm against lot documents | Eloralintide is listed in the metabolic research catalog. Early clinical disclosures cited in the catalog do not establish product-specific efficacy, safety or equivalence to the tested preparation. |
| Epithalon (Epitalon) Longevity | 390.35 g/mol | Not listed — confirm against lot documents | Epithalon, also spelled Epitalon, is studied in telomere and aging-related experimental systems. Cell and animal findings do not establish human lifespan extension or reversal of biological age. |
| FGL (FGLL) Cognitive | 1639.85 g/mol | Not listed — confirm against lot documents | FGL is studied in neural cell-adhesion-related signaling. Rodent learning and cellular-injury experiments provide preclinical context, not demonstrated human neuroprotection. |
| Follistatin 344 Growth Factors | ~37500 g/mol | Not listed — confirm against lot documents | Follistatin 344 literature includes gene-transfer experiments using AAV constructs. Those studies do not establish equivalent effects from a supplied follistatin protein vial. |
| FOXO4-DRI Longevity | ~5358 g/mol | Not listed — confirm against lot documents | FOXO4-DRI has cultured-cell and aged-mouse research on senescence-related pathways. Early preclinical findings do not establish human rejuvenation, safety or efficacy. |
| GHK-Cu (Copper Peptide) Recovery & Repair | 340.38 g/mol | Not listed — confirm against lot documents | GHK-Cu, the copper peptide complex, has cell, animal and topical-skin literature summarized by Pickart and Margolina. Gene-expression findings do not demonstrate reversal of human aging or validate this vial. |
| GHRH (GH Releasing Hormone) Growth Hormone | 5040.4 g/mol | Not listed — confirm against lot documents | Growth-hormone-releasing hormone (GHRH) is an endocrine signal studied for pituitary growth hormone release. Foundational characterization studies provide parent-hormone context, not lot identity confirmation. |
| GHRP-1 Growth Hormone | 956.13 g/mol | Not listed — confirm against lot documents | GHRP-1 belongs to the growth hormone-releasing peptide class. Foundational class studies do not establish this specific material’s comparative potency or endocrine selectivity. |
| GHRP-2 Growth Hormone | 817.97 g/mol | Not listed — confirm against lot documents | GHRP-2, also known as pralmorelin, is studied for growth hormone release. Its research context does not support a blanket claim that it outperforms every other growth hormone secretagogue. |
| GHRP-6 Growth Hormone | 873.01 g/mol | Not listed — confirm against lot documents | GHRP-6 is a growth hormone secretagogue. The catalog cites animal cardiac and gastric-injury research, which does not establish equivalent tissue-protection effects in humans. |
| Glepaglutide GLP-1 & Metabolic | ~4400 g/mol | Not listed — confirm against lot documents | Glepaglutide is studied in short-bowel-syndrome research. Human trials examined absorption and parenteral-support outcomes with defined formulations, not this catalog vial. |
| GLOW Blend (GHK-Cu + BPC-157 + TB-500) Recovery & Repair | Mixture | Not listed — confirm against lot documents | GLOW-70 combines GHK-Cu, BPC-157 and TB-500 in a 70 mg catalog vial. No blend-specific controlled study is cited; component findings do not establish GLOW’s efficacy, safety or synergy. |
| Glutathione Longevity | 307.32 g/mol | Not listed — confirm against lot documents | Glutathione is a tripeptide involved in cellular redox balance. Human studies of specific preparations and biomarkers do not establish a broad clinical benefit or make this vial a poisoning antidote. |
| Gonadorelin (GnRH) Reproductive | 1182.29 g/mol | Not listed — confirm against lot documents | Gonadorelin is a gonadotropin-releasing hormone (GnRH) research material. Human studies examined pituitary and reproductive responses in specific endocrine conditions, not this catalog preparation. |
| HCG Growth Factors | Not listed | Not listed — confirm against lot documents | Human chorionic gonadotropin (hCG) is studied in reproductive endocrine signaling. Clinical fertility and hormone studies concern defined preparations and populations, not verification of this inventory. |
| Hexarelin Growth Hormone | 887.04 g/mol | Not listed — confirm against lot documents | Hexarelin is studied in growth hormone signaling and cardiac CD36 research. Preclinical ischemia experiments concern specific animal models, not demonstrated cardioprotection from this vial. |
| HMG Growth Factors | Not listed | Not listed — confirm against lot documents | Human menopausal gonadotropin (hMG) has clinical fertility literature. Outcomes from regulated clinical preparations cannot be assumed for a catalog research material carrying the same name. |
| Humanin Longevity | Not listed | Not listed — confirm against lot documents | Humanin is a mitochondrial-derived peptide studied in cell-survival and metabolic models. Longevity associations and preclinical protective effects do not demonstrate an anti-aging treatment benefit. |
| IGF-1 DES Growth Factors | Not listed | Not listed — confirm against lot documents | IGF-1 DES, or Des(1-3) IGF-I, has biochemical review and animal evidence on altered IGF-binding-protein interactions. Results depend on the construct and model, not a universal potency multiplier.2 cited references → |
| IGF-1 LR3 (Receptor Grade) Growth Factors | Not listed | Not listed — confirm against lot documents | IGF-1 LR3 is the long-R3 IGF-I analogue discussed in guinea-pig studies of organ growth and circulating IGF-system measures. Those findings do not establish a fixed half-life or potency for this vial.1 cited reference → |
| IGF-2 LR3 Growth Factors | Not listed | Not listed — confirm against lot documents | IGF-2 LR3 remains an unconfirmed catalog construct. Native IGF-II receptor literature provides background only; no direct peer-reviewed validation of this specific LR3 material was identified.1 cited reference → |
| Ipamorelin Growth Hormone | 711.85 g/mol | Not listed — confirm against lot documents | Ipamorelin is a growth hormone secretagogue. Raun and colleagues studied selectivity and growth hormone release in rat pituitary cells and swine, not clinical benefits for this vial. |
| Kisspeptin-10 Reproductive | Not listed | Not listed — confirm against lot documents | Kisspeptin-10 is studied in reproductive hormone signaling. Findings for kisspeptin-54 in fertility trials concern a different peptide, not direct evidence for kisspeptin-10. |
| KLOW Blend (KPV + GHK-Cu + BPC-157 + TB-500) Recovery & Repair | Mixture | Not listed — confirm against lot documents | KLOW-80 combines KPV, GHK-Cu, BPC-157 and TB-500 in an 80 mg catalog vial. Constituent literature does not establish direct evidence for KLOW as a combined formulation. |
| KPV (α-MSH 11-13) Melanocortin | Not listed | Not listed — confirm against lot documents | KPV peptide is the Lys-Pro-Val fragment associated with alpha-MSH research. Reviews and mouse intestinal-inflammation experiments provide preclinical context, not proven treatment benefits in humans. |
| Larazotide Acetate Specialty | 1149.30 g/mol | Not listed — confirm against lot documents | Larazotide acetate is studied in intestinal-barrier and celiac-disease research. The catalog notes that a phase 3 program did not meet its primary endpoint, so earlier results do not establish clinical efficacy. |
| Liraglutide GLP-1 & Metabolic | 3751.20 g/mol | Not listed — confirm against lot documents | Liraglutide is a GLP-1 analogue. LEADER examined cardiovascular outcomes in high-risk adults with type 2 diabetes, while SCALE examined weight-management outcomes in a different population.2 cited references → |
| Livagen Bioregulators | Not listed | Not listed — confirm against lot documents | Livagen is listed for chromatin and liver-related research. The available narrative does not provide enough product-specific evidence to establish clinical liver-function benefits. |
| LL-37 (CAP-18) Immune | Not listed | Not listed — confirm against lot documents | LL-37, the human cathelicidin peptide, has antimicrobial and immune-signaling literature. Cell and biofilm experiments do not establish infection treatment or wound-healing benefits from this vial. |
| Maridebart Cafraglutide (MariTide) GLP-1 & Metabolic | ~6800 g/mol | Not listed — confirm against lot documents | MariTide, or maridebart cafraglutide, literature concerns a defined antibody-peptide conjugate. Preclinical and phase 1 findings do not establish equivalence to an unspecified material carrying that name.1 cited reference → |
| Matrixyl (Palmitoyl Pentapeptide-4) Specialty | 802.10 g/mol | Not listed — confirm against lot documents | Matrixyl, or palmitoyl pentapeptide-4, has fibroblast and topical-formulation literature. Cosmetic appearance outcomes apply to the tested formulations, not this catalog reagent. |
| Mazdutide GLP-1 & Metabolic | 4366.79 g/mol | Not listed — confirm against lot documents | Mazdutide, also called IBI362, has early clinical research in adults with overweight or obesity. A phase 1b trial examined safety, tolerability and pharmacokinetics of a defined preparation, not this reagent.1 cited reference → |
| Melanotan I Melanocortin | 1646.85 g/mol | Not listed — confirm against lot documents | Melanotan I research includes related clinical afamelanotide literature in erythropoietic protoporphyria. Clinical formulation findings do not verify this material or establish general ultraviolet protection. |
| Melanotan II Melanocortin | 1024.18 g/mol | Not listed — confirm against lot documents | Melanotan II is studied in melanocortin signaling and pigmentation research. Experimental findings do not establish safe tanning, ultraviolet protection or clinical benefits from this vial. |
| MGF (Mechano Growth Factor) Recovery & Repair | Not listed | Not listed — confirm against lot documents | Mechano growth factor (MGF) literature examines IGF-related responses to mechanical loading and muscle-cell biology. Endogenous-expression findings do not establish effects of supplied synthetic MGF. |
| MK-677 (Ibutamoren) GLP-1 & Metabolic | 528.67 g/mol | Not listed — confirm against lot documents | MK-677, also called ibutamoren, is a non-peptide ghrelin-receptor agonist. Human studies examined growth hormone, IGF-1 and body-composition measures, not risk-free use of this inventory. |
| Mod GRF 1-29 (CJC-1295 No DAC) Growth Hormone | Not listed | Not listed — confirm against lot documents | Mod GRF 1-29 is also marketed as CJC-1295 No DAC. The cited long-acting CJC-1295 studies concern the DAC construct and do not directly validate this non-DAC material.2 cited references → |
| MOTS-c Longevity | Not listed | Not listed — confirm against lot documents | MOTS-c is a mitochondrial-derived peptide studied in metabolic and exercise-response research. Mouse experiments and human observational measurements do not establish treatment benefits from this vial. |
| N-Acetyl Semax Amidate Cognitive | Not listed | Not listed — confirm against lot documents | N-Acetyl Semax Amidate is a modified Semax-family material. Acetylation and amidation provide a design rationale, but do not transfer Semax’s clinical evidence or prove improved stability for this construct. |
| NAD+ Longevity | 663.43 g/mol | Not listed — confirm against lot documents | NAD+ is a metabolic coenzyme, not a peptide. Reviews describe its roles in cellular metabolism and aging biology; studies of precursors or other preparations cannot establish effects of this material. |
| NAP (Davunetide) Cognitive | 824.86 g/mol | Not listed — confirm against lot documents | NAP, also called davunetide, has preclinical neuroprotection literature and human studies. Its phase 3 progressive supranuclear palsy trial did not meet the primary endpoint, limiting clinical benefit claims. |
| Orforglipron GLP-1 & Metabolic | 600.66 g/mol | Not listed — confirm against lot documents | Orforglipron is a non-peptide GLP-1 receptor agonist. Separate phase 2 studies examined obesity and type 2 diabetes using defined oral preparations, not this research inventory.2 cited references → |
| Oxytocin Reproductive | 1007.19 g/mol | Not listed — confirm against lot documents | Oxytocin has endocrine and social-behavior research spanning clinical and experimental models. Small behavioral studies do not establish broad cognitive or social benefits for this catalog material. |
| P21 (P021) Cognitive | Not listed | Not listed — confirm against lot documents | P21, also called P021, has mouse-model research on memory, neurogenesis and tau-related measures. These preclinical findings do not establish human cognitive benefits or validate Adamax’s modification. |
| Pancragen Bioregulators | Not listed | Not listed — confirm against lot documents | Pancragen is listed for pancreatic and metabolic research. The available study detail does not establish improved insulin sensitivity or prevention of diabetes. |
| PE-22-28 Specialty | Not listed | Not listed — confirm against lot documents | PE-22-28 is discussed alongside spadin-related potassium-channel research. Findings for a named parent peptide cannot establish this fragment’s identity, speed of action or human antidepressant effects. |
| PEG-MGF (Pegylated MGF) Recovery & Repair | Not listed | Not listed — confirm against lot documents | PEG-MGF is marketed as a PEG-modified MGF material. Parent-MGF literature and general PEG-conjugation principles do not establish this construct’s persistence, distribution or functional effects. |
| PEG-MOTS-c Longevity | ~6000 g/mol | Not listed — confirm against lot documents | PEG-MOTS-c is marketed as a modified MOTS-c material. Native MOTS-c studies and general PEG-conjugation principles do not prove this construct’s stability, pharmacokinetics or human benefits. |
| Pemvidutide GLP-1 & Metabolic | ~4900 g/mol | Not listed — confirm against lot documents | Pemvidutide has clinical research in metabolic dysfunction-associated steatohepatitis (MASH). IMPACT studied adults with biopsy-confirmed disease and a defined clinical formulation, not this vial.1 cited reference → |
| Petrelintide GLP-1 & Metabolic | ~4200 g/mol | Not listed — confirm against lot documents | Petrelintide is an amylin analogue studied in metabolic research. The catalog cites early clinical program reporting, not verified evidence of weight-loss outcomes or favorable tolerability for this vial. |
| Pinealon Bioregulators | Not listed | Not listed — confirm against lot documents | Pinealon is listed for nervous-system and aging-related research. Sleep and melatonin claims in the catalog lack enough construct-specific study detail to support clinical conclusions. |
| PNC-27 Specialty | Not listed | Not listed — confirm against lot documents | PNC-27 is studied in experimental cancer-cell systems involving membrane-associated HDM-2. Cell-killing findings do not establish a cancer treatment or selective safety in humans. |
| Pramlintide GLP-1 & Metabolic | 3949.40 g/mol | Not listed — confirm against lot documents | Pramlintide is an amylin analogue with clinical metabolic research. Studies of pramlintide alone and with metreleptin address different preparations and do not establish effects of this vial. |
| Prostamax Bioregulators | Not listed | Not listed — confirm against lot documents | Prostamax is listed for prostate-related research. The catalog does not provide enough product-specific study detail to establish clinical urinary or anti-inflammatory benefits. |
| PT-141 (Bremelanotide) Reproductive | 1025.18 g/mol | Not listed — confirm against lot documents | PT-141, or bremelanotide, has human clinical literature on sexual-function outcomes. Those trials studied defined clinical formulations, not the identity, safety or effects of this research vial. |
| Retatrutide GLP-1 & Metabolic | 4603.27 g/mol | Not listed — confirm against lot documents | Retatrutide is studied as a GIP, GLP-1 and glucagon receptor agonist. A phase 2 obesity trial measured body-weight outcomes and adverse events, without directly comparing it with tirzepatide.1 cited reference → |
| Selank Cognitive | 751.86 g/mol | Not listed — confirm against lot documents | Selank is a tuftsin-related research peptide. The catalog cites experimental and clinical anxiety-related literature, not established equivalence to other treatments or risk-free use of this vial. |
| Semaglutide GLP-1 & Metabolic | 4113.58 g/mol | Not listed — confirm against lot documents | Semaglutide is a GLP-1 receptor agonist. STEP 1 studied body-weight outcomes in adults with overweight or obesity using a defined clinical formulation, not this research vial.1 cited reference → |
| Semax Cognitive | 813.93 g/mol | Not listed — confirm against lot documents | Semax is an ACTH-fragment analogue. Rat studies examined BDNF and TrkB responses; this evidence does not establish equivalent effects for Adamax or other modified Semax-family materials. |
| Sermorelin Growth Hormone | 3357.93 g/mol | Not listed — confirm against lot documents | Sermorelin is a GHRH-fragment analogue. Published reviews discuss its endocrine and clinical research context; historical clinical use does not verify this catalog material’s safety or identity. |
| SLU-PP-332 GLP-1 & Metabolic | 445.49 g/mol | Not listed — confirm against lot documents | SLU-PP-332 is a non-peptide compound studied in estrogen-related receptor signaling. Mouse endurance and metabolism experiments do not establish human exercise benefits or safety. |
| SNAP-8 (Acetyl Octapeptide-3) Specialty | 905.99 g/mol | Not listed — confirm against lot documents | SNAP-8, or acetyl octapeptide-3, has limited topical-formulation evidence described in the catalog. Small formulation studies do not establish reliable cosmetic effects for this material. |
| SS-31 (Elamipretide) Longevity | 640.8 g/mol | Not listed — confirm against lot documents | SS-31, also called elamipretide, is studied in mitochondrial membrane and cardiolipin research. Clinical studies address specific preparations and conditions; regulatory designations alone do not establish successful outcomes. |
| Survodutide GLP-1 & Metabolic | 4493.10 g/mol | Not listed — confirm against lot documents | Survodutide, or BI 456906, has receptor-pharmacology and preclinical literature. The cited discovery paper includes cell and animal experiments, not validation of this inventory or a clinical benefit claim.1 cited reference → |
| TB-500 (Thymosin Beta-4) Recovery & Repair | Not listed | Not listed — confirm against lot documents | TB-500 is a name used for thymosin-beta-4-related materials. Parent-peptide wound research and analytical work on an acetylated fragment do not establish equivalence or identify this catalog construct. |
| Tesamorelin Growth Hormone | 5135.83 g/mol | Not listed — confirm against lot documents | Tesamorelin is a GHRH analogue. Clinical studies examined visceral and liver-fat outcomes in defined populations and formulations, not general fat-loss effects from this research vial. |
| Tesamorelin + Ipamorelin Blend Growth Hormone | Mixture | Not listed — confirm against lot documents | Tesamorelin and ipamorelin have separate compound-specific literature. Tesamorelin clinical findings do not establish clinical outcomes or synergy for this commercial blend. |
| Testagen Bioregulators | Not listed | Not listed — confirm against lot documents | Testagen is listed for reproductive endocrine research. The available narrative does not substantiate clinical testosterone or reproductive-function benefits. |
| Thymalin Immune | Not listed | Not listed — confirm against lot documents | Thymalin is listed as a thymus-related research material. The catalog’s broad longevity and immune claims lack enough study detail here to establish product-specific clinical conclusions. |
| Thymosin Alpha-1 Immune | 3108.27 g/mol | Not listed — confirm against lot documents | Thymosin alpha-1 has immunology and condition-specific clinical literature. Results vary by preparation, population and design, and do not establish general immune-boosting benefits for this inventory. |
| Thyrotropin (TRH) Specialty | 362.38 g/mol | Not listed — confirm against lot documents | Thyrotropin-releasing hormone (TRH) is an endocrine research signal. Diagnostic and experimental nervous-system literature does not establish cognitive or antidepressant benefits from this material. |
| Tirzepatide GLP-1 & Metabolic | 4813.45 g/mol | Not listed — confirm against lot documents | Tirzepatide activates GIP and GLP-1 receptors. SURPASS-2 compared glucose-control and body-weight outcomes with semaglutide in adults with type 2 diabetes; findings apply to the tested formulations.1 cited reference → |
| Triptorelin Reproductive | 1311.45 g/mol | Not listed — confirm against lot documents | Triptorelin is a GnRH analogue with clinical literature on defined depot preparations. That evidence does not establish effects of this vial or substantiate hormone restart claims. |
| Trofinetide (NNZ-2566) Cognitive | 341.4 g/mol | Not listed — confirm against lot documents | Trofinetide, also called NNZ-2566, has clinical Rett-syndrome literature. LAVENDER evaluated condition-specific behavior and clinical-impression measures using a defined preparation, not this material. |
| Vesilute Bioregulators | Not listed | Not listed — confirm against lot documents | Vesilute is listed for bladder-related research. Product-specific study detail is insufficient here to substantiate improved bladder function or reduced incontinence. |
| Vesugen Bioregulators | Not listed | Not listed — confirm against lot documents | Vesugen is listed for vascular-system research. Broad vascular and atherosclerosis claims in the catalog do not establish product-specific clinical benefits. |
| VIP Specialty | 3326.8 g/mol | Not listed — confirm against lot documents | Vasoactive intestinal peptide (VIP) has receptor-signaling and condition-specific human pulmonary literature. Findings for tested preparations do not establish broad pulmonary or immune benefits for this vial. |
| VK2735 GLP-1 & Metabolic | ~4500 g/mol | Not listed — confirm against lot documents | VK2735 is studied in GIP and GLP-1 receptor research. VENTURE trial reporting concerns a defined clinical preparation and does not verify this laboratory material.1 cited reference → |
| Wolverine Blend (BPC-157 + TB-500) Recovery & Repair | Mixture | Not listed — confirm against lot documents | Wolverine Blend combines catalog-labelled BPC-157 and TB-500. Component studies do not establish the fixed blend’s efficacy, safety or synergy. |
Molecular masses and sequences are catalog specifications. They are not lot test results, and purity does not by itself establish identity or vial quantity. Evidence summaries describe the studied materials and models, not this product. Related reading: IGF-1 growth-factor analogs and the Semax family article.
Research Use Only. All products are sold strictly for in-vitro laboratory research. Not for human consumption, therapeutic, veterinary or any in-vivo use. This directory provides no dosing or administration guidance.
